Earendil Labs vs Iambic Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.
About
Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.
AI drug discovery biotech with $1.7B Takeda deal (Feb 2026). Lead drug IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1. $100M+ raised (2025). Founded 2019, San Diego.
About
Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company built proprietary machine learning models for structure-based drug design, training its systems on large datasets of protein-ligand interactions to accelerate hit identification, lead optimization, and candidate selection. This computational-first approach compresses timelines that traditionally require years of iterative chemistry work into months.\n\nIambic's lead asset, IAM1363, is a brain-penetrant HER2 inhibitor targeting HER2-mutated cancers including non-small cell lung cancer and breast cancer with brain metastases — a patient population with limited treatment options and high unmet need. The candidate entered Phase 1 clinical trials as a direct output of Iambic's AI design pipeline, validating the platform's ability to produce clinically viable molecules. The company's AI models are designed to simultaneously optimize for potency, selectivity, and the blood-brain barrier permeability that makes IAM1363 differentiated from approved HER2 inhibitors.\n\nIambic secured a $1.7B collaboration deal with Takeda in February 2026, one of the largest AI drug discovery partnerships in the industry's history, validating both the platform and its pipeline at the highest commercial level. The company raised over $100M in 2025 and has positioned itself alongside Recursion and Insilico Medicine as a leading AI-first biotech with clinical-stage proof points. The Takeda deal provides non-dilutive capital and development resources while preserving Iambic's pipeline optionality across multiple oncology indications.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.